{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:38:00Z","timestamp":1785897480596,"version":"3.56.0"},"reference-count":115,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Pancreatic neuroendocrine neoplasms (panNENs) are heterogeneous neoplasms with neuroendocrine differentiation that show peculiar clinical and histomorphological features, with variable prognosis. In recent years, advances in knowledge regarding the pathophysiology and heterogeneous clinical presentation, as well as the availability of different diagnostic procedures for panNEN diagnosis and novel therapeutic options for patient clinical management, has led to the recognition of the need for an active multidisciplinary discussion for optimal patient care. Molecular imaging with positron emission tomography\/computed tomography (PET\/CT) has become indispensable for the management of panNENs. Several PET radiopharmaceuticals can be used to characterize either panNEN receptor expression or metabolism. The aim of this review is to offer an overview of all the currently used radiopharmaceuticals and of the new upcoming tracers for pancreatic neuroendocrine tumors (panNETs), and their clinical impact on therapy management. [68Ga]Ga-DOTA-peptide PET\/CT (SSA-PET\/CT) has high sensitivity, specificity, and accuracy and is recommended for the staging and restaging of any non-insulinoma well-differentiated panNEN cases to carry out detection of unknown primary tumor sites or early relapse and for evaluation of in vivo somatostatin receptors expression (SRE) to select patient candidates for peptide receptor radiometabolic treatment (PRRT) with 90Y or 177Lu and\/or cold analogs. SSA-PET\/CT also has a strong impact on clinical management, leading to a change in treatment in approximately a third of the cases. Its role for treatment response assessment is still under debate due to the lack of standardized criteria, even though some semiquantitative parameters seem to be able to predict response. [18F]FDG PET\/CT generally shows low sensitivity in small growing and well-differentiated neuroendocrine tumors (NET; G1 and G2), while it is of utmost importance in the evaluation and management of high-grade NENs and also provides important prognostic information. When positive, [18F]FDG PET\/CT impacts therapeutical management, indicating the need for a more aggressive treatment regime. Although FDG positivity does not exclude the patient from PRRT, several studies have demonstrated that it is certainly useful to predict response, even in this setting. The role of [18F]FDOPA for the study of panNET is limited by physiological uptake in the pancreas and is therefore not recommended. Moreover, it provides no information on SRE that has crucial clinical management relevance. Early acquisition of the abdomen and premedication with carbidopa may be useful to increase the accuracy, but further studies are needed to clarify its utility. GLP-1R agonists, such as exendin-4, are particularly useful for benign insulinoma detection, but their accuracy decreases in the case of malignant insulinomas. Being a whole-body imaging technique, exendin-PET\/CT gives important preoperative information on tumor size and localization, which is fundamental for surgical planning as resection (enucleation of the lesion or partial pancreatic resection) is the only curative treatment. New upcoming tracers are under study, such as promising SSTR antagonists, which show a favorable biodistribution and higher tumor-to-background ratio that increases tumor detection, especially in the liver. [68Ga]pentixafor, an in vivo marker of CXCR4 expression associated with the behavior of more aggressive tumors, seems to only play a limited role in detecting well-differentiated NET since there is an inverse expression of SSTR2 and CXCR4 in G1 to G3 NETs with an elevation in CXCR4 and a decrease in SSTR2 expression with increasing grade. Other tracers, such as [68Ga]Ga-PSMA, [68Ga]Ga-DATA-TOC, [18F]SiTATE, and [18F]AlF-OC, are also under investigation.<\/jats:p>","DOI":"10.3390\/diagnostics10121059","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T12:24:39Z","timestamp":1607343879000},"page":"1059","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Role of PET\/CT and Therapy Management of Pancreatic Neuroendocrine Tumors"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7321-1966","authenticated-orcid":false,"given":"Diletta","family":"Calabr\u00f2","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, IRCCS Azienda Ospedaliera-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Nuclear Medicine, DIMES University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-4146","authenticated-orcid":false,"given":"Giulia","family":"Argalia","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, IRCCS Azienda Ospedaliera-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Nuclear Medicine, DIMES University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ambrosini","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, IRCCS Azienda Ospedaliera-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Nuclear Medicine, DIMES University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1148\/rg.2020200025","article-title":"Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification","volume":"40","author":"Khanna","year":"2020","journal-title":"RadioGraphics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5858\/arpa.2019-0338-RA","article-title":"A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms with a Focus on the New World Health Organization Classification","volume":"143","author":"Fang","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3348\/kjr.2018.0040","article-title":"What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?","volume":"20","author":"Choe","year":"2019","journal-title":"Korean J. Radiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000458155","article-title":"ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation","volume":"105","author":"Knigge","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/MED.0b013e32835570f1","article-title":"A rationale for multidisciplinary care in treating neuroendocrine tumours","volume":"19","author":"Metz","year":"2012","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40842-018-0066-3","article-title":"Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","volume":"4","author":"Uri","year":"2018","journal-title":"Clin. Diabetes Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Burkett, B.J., Dundar, A., Young, J.R., Packard, A.T., Johnson, G.B., Halfdanarson, T.R., Eiring, R.A., Gansen, D.N., Patton, C.M., and Kendi, A.T. (2020). How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology, 201745.","DOI":"10.1148\/radiol.2020201745"},{"key":"ref_9","first-page":"1205","article-title":"Implementation of multidisciplinary team in the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasm","volume":"19","author":"Zhang","year":"2016","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi Chin. J. Gastrointest. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Magi, L., Mazzuca, F., Rinzivillo, M., Arrivi, G., Pilozzi, E., Prosperi, D., Iannicelli, E., Mercantini, P., Rossi, M., and Pizzichini, P. (2019). Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. J. Clin. Med., 8.","DOI":"10.3390\/jcm8060910"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"R184","DOI":"10.1530\/EC-19-0413","article-title":"Multidisciplinary team management of carcinoid heart disease","volume":"8","author":"Steeds","year":"2019","journal-title":"Endocr. Connect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2478\/raon-2019-0040","article-title":"The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: The radiologist\u2019s challenge","volume":"53","author":"Granata","year":"2019","journal-title":"Radiol. Oncol."},{"key":"ref_13","unstructured":"Sharma, P., Arora, S., Dhull, V.S., Naswa, N., Kumar, R., Ammini, A.C., and Bal, C. (2020, October 14). Evaluation of (68)Ga-DOTANOC PET\/CT Imaging in a Large Exclusive Population of Pancreatic Neuroendocrine Tumors, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/25134801\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1007\/s00259-014-2850-3","article-title":"Comparison of the prognostic values of 68Ga-DOTANOC PET\/CT and 18F-FDG PET\/CT in patients with well-differentiated neuroendocrine tumor","volume":"41","author":"Sharma","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/RLU.0000000000000257","article-title":"Predictive value of 68Ga-DOTANOC PET\/CT in patients with suspicion of neuroendocrine tumors: Is its routine use justified?","volume":"39","author":"Sharma","year":"2014","journal-title":"Clin. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.109.071712","article-title":"68Ga-DOTANOC PET\/CT Clinical Impact in Patients with Neuroendocrine Tumors","volume":"51","author":"Ambrosini","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s00261-012-9871-9","article-title":"Role of PET\/CT in the functional imaging of endocrine pancreatic tumors","volume":"37","author":"Rufini","year":"2012","journal-title":"Abdom. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12020-012-9631-1","article-title":"Diagnostic performance of Gallium-68 somatostatin receptor PET and PET\/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: A meta-analysis","volume":"42","author":"Treglia","year":"2012","journal-title":"Endocrine"},{"key":"ref_19","first-page":"364","article-title":"Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors","volume":"54","author":"Wild","year":"2013","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_20","first-page":"1598","article-title":"68Ga-DOTATATE PET\/CT, 99mTc-HYNIC-octreotide SPECT\/CT, and whole-body MR imaging in detection of neuroendocrine tumors: A prospective trial","volume":"55","author":"Etchebehere","year":"2014","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_21","first-page":"69","article-title":"Somatostatin receptor based PET\/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma","volume":"60","author":"Sharma","year":"2016","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging","volume":"105","author":"Sundin","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","unstructured":"(2020, May 20). Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors with 90Y-DOTATOC: Is Treatment Response Predictable by Pre-Therapeutic Uptake of 68Ga-DOTATOC?\u2014ScienceDirect. Available online: https:\/\/www-sciencedirect-com.ezproxy.unibo.it\/science\/article\/pii\/S2211568413002325."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1007\/s00261-019-01994-5","article-title":"The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: Focus on PET and MRI","volume":"44","author":"Rozenblum","year":"2019","journal-title":"Abdom. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lancellotti, F., Sacco, L., Cerasari, S., Bellato, V., Cicconi, S., Ciardi, A., Muttillo, E.M., Feola, T., Caronna, R., and Chirletti, P. (2019). Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: Case report and literature review. World J. Surg. Oncol., 17.","DOI":"10.1186\/s12957-019-1660-2"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/RLU.0b013e3181b06b42","article-title":"Intrapancreatic accessory spleen diagnosed on radionuclide imaging","volume":"34","author":"Belkhir","year":"2009","journal-title":"Clin. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/RLU.0000000000000601","article-title":"Intrapancreatic accessory spleen detected by 68Ga DOTANOC PET\/CT and 99mTc-colloid SPECT\/CT scintigraphy","volume":"40","author":"Collarino","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Bauckneht, M., Albano, D., Annunziata, S., Santo, G., Guglielmo, P., Frantellizzi, V., Branca, A., Ferrari, C., Vento, A., and Mirabile, A. (2020). Somatostatin Receptor PET\/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis. Diagnostics, 10.","DOI":"10.3390\/diagnostics10080598"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00259-009-1349-9","article-title":"68Ga-DOTA-NOC PET\/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours","volume":"37","author":"Ambrosini","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","article-title":"Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET\/CT","volume":"37","author":"Prasad","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s12149-014-0856-3","article-title":"(68)Ga-DOTATATE PET\/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin","volume":"28","author":"Alonso","year":"2014","journal-title":"Ann. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/RLU.0b013e31823ea730","article-title":"68Ga-DOTANOC PET\/CT in patients with carcinoma of unknown primary of neuroendocrine origin","volume":"37","author":"Naswa","year":"2012","journal-title":"Clin. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s00330-016-4475-3","article-title":"The added value of 68Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin","volume":"27","author":"Kazmierczak","year":"2017","journal-title":"Eur. Radiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000324770","article-title":"Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review","volume":"93","author":"Capurso","year":"2011","journal-title":"Neuroendocrinology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1148\/radiol.13122501","article-title":"Neuroendocrine Tumor Recurrence: Diagnosis with 68 Ga-DOTATATE PET\/CT","volume":"270","author":"Haug","year":"2014","journal-title":"Radiology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2967\/jnumed.115.162719","article-title":"Prognostic Value of 68Ga-DOTANOC PET\/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas","volume":"56","author":"Ambrosini","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4149\/neo_2018_180328N209","article-title":"Prognostic value of functional tumor burden on 68Ga-DOTATOC PET\/CT in patients with pancreatic neuro-endocrine tumors","volume":"66","author":"Ohnona","year":"2019","journal-title":"Neoplasma"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13550-020-00651-z","article-title":"Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET\/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours","volume":"10","author":"Kim","year":"2020","journal-title":"EJNMMI Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","article-title":"The Impact of 68Ga-DOTATATE PET\/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom","volume":"57","author":"Skoura","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jso.25812","article-title":"Impact of initial imaging with gallium-68 dotatate PET\/CT on diagnosis and management of patients with neuroendocrine tumors","volume":"121","author":"Crown","year":"2020","journal-title":"J. Surg. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/MPA.0000000000001625","article-title":"Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography\u2013Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors","volume":"49","author":"Ghobrial","year":"2020","journal-title":"Pancreas"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ejrad.2015.06.024","article-title":"Clinical value of 68Ga-DOTATATE-PET\/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET)","volume":"84","author":"Albanus","year":"2015","journal-title":"Eur. J. Radiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00259-013-2369-z","article-title":"Role of 18FDG PET\/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours","volume":"40","author":"Severi","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2147\/OTT.S202867","article-title":"Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights","volume":"13","author":"Starr","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2967\/jnumed.115.158899","article-title":"Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate","volume":"56","author":"Teunissen","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1245\/s10434-016-5550-3","article-title":"Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1\u2013G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases","volume":"23","author":"Bertani","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00259-013-2402-2","article-title":"Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: Factors associated with response and suggestions for therapeutic sequence","volume":"40","author":"Campana","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Luo, Y., Chen, J., Huang, K., Lin, Y., Chen, M., Xu, L., Li, Z.-P., and Feng, S.-T. (2017). Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3150-7"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41416-019-0558-7","article-title":"Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: Comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)","volume":"121","author":"Custodio","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","article-title":"68Ga-DOTATATE PET\/CT for the Early Prediction of Response to Somatostatin Receptor\u2013Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors","volume":"51","author":"Haug","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.radonc.2019.09.003","article-title":"68Ga-DOTATATE PET\/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours","volume":"141","author":"Sharma","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40644-020-00335-w","article-title":"Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy","volume":"20","author":"Huizing","year":"2020","journal-title":"Cancer Imaging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11307-018-1252-5","article-title":"Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy","volume":"21","author":"Werner","year":"2019","journal-title":"Mol. Imaging Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/MNM.0000000000001231","article-title":"Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET\/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors?","volume":"41","year":"2020","journal-title":"Nucl. Med. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1038\/s41598-020-61075-2","article-title":"Radioguided surgery with \u03b2-radiation in pancreatic Neuroendocrine Tumors: A feasibility study","volume":"10","author":"Collamati","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clinimag.2020.05.035","article-title":"Ga-68 DOTA-peptides and F-18 FDG PET\/CT in patients with neuroendocrine tumor: A review","volume":"67","author":"Evangelista","year":"2020","journal-title":"Clin. Imaging"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Carideo, L., Prosperi, D., Panzuto, F., Magi, L., Pratesi, M.S., Rinzivillo, M., Annibale, B., and Signore, A. (2019). Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET\/CT in the Management of GEP-NENs: A Systematic Review. J. Clin. Med., 8.","DOI":"10.3390\/jcm8071032"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00595-018-1703-2","article-title":"Clinical role of fludeoxyglucose (18F) positron emission tomography\/computed tomography (18F-FDG PET\/CT) in patients with pancreatic neuroendocrine tumors","volume":"49","author":"Matsumoto","year":"2019","journal-title":"Surg. Today"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2967\/jnumed.116.178095","article-title":"Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET\/CT on Clinical Management in Patients with Neuroendocrine Tumors","volume":"58","author":"Panagiotidis","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.23469","article-title":"Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG","volume":"112","author":"Kayani","year":"2008","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2340389","DOI":"10.1155\/2018\/2340389","article-title":"Clinical and Prognostic Value of PET\/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms","volume":"2018","author":"Zhang","year":"2018","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3892\/ijo.2014.2570","article-title":"(18)F-FDG PET\/CT can be used to detect non-functioning pancreatic neuroendocrine tumors","volume":"45","author":"Luo","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13550-019-0585-7","article-title":"Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET\/CT","volume":"9","author":"Majala","year":"2019","journal-title":"EJNMMI Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MPA.0000000000000745","article-title":"Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography\/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions","volume":"46","author":"Cingarlini","year":"2017","journal-title":"Pancreas"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual Somatostatin Receptor\/FDG PET\/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Zhang, J., Liu, Q., Singh, A., Schuchardt, C., Kulkarni, H.R., and Baum, R.P. (2020). Prognostic Value of 18F-FDG PET\/CT in a Large Cohort of 495 Patients with Advanced Metastatic Neuroendocrine Neoplasms (NEN) Treated with Peptide Receptor Radionuclide Therapy (PRRT). J. Nucl. Med.","DOI":"10.1055\/s-0039-1683742"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00259-016-3497-z","article-title":"The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: Predicting and looking at the possible case scenarios","volume":"43","author":"Basu","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ostwal, V., Basu, S., Bhargava, P., Shah, M., Parghane, R.V., Srinivas, S., Chaudhari, V., Bhandare, M.S., Shrikhande, S.V., and Ramaswamy, A. (2020). Capecitabine-Temozolomide (CAPTEM) in advanced Grade 2 and grade 3 Neuroendocrine neoplasms (NENs)\u2014Benefits of chemotherapy in NENs with significant 18FDG uptake. Neuroendocrinology.","DOI":"10.1159\/000511987"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000443172","article-title":"ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas","volume":"103","author":"Sorbye","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000368609","article-title":"The role of combined Ga-DOTANOC and (18)FDG PET\/CT in the management of patients with pancreatic neuroendocrine tumors","volume":"100","author":"Partelli","year":"2014","journal-title":"Neuroendocrinology"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Chondrogiannis, S., Cristina Marzola, M., Al-Nahhas, A., Venkatanarayana, T.D., Mazza, A., Opocher, G., and Rubello, D. (2013). Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl. Med. Commun., 1.","DOI":"10.1097\/MNM.0000000000000008"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","article-title":"Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours","volume":"36","author":"Haug","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","article-title":"Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours","volume":"35","author":"Ambrosini","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/cen.14202","article-title":"Solid pseudopapillary tumour should be part of differential diagnosis of focal pancreatic lesions with increased 18F-FDOPA uptake","volume":"93","author":"Somme","year":"2020","journal-title":"Clin. Endocrinol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/RLU.0000000000001318","article-title":"18F-DOPA PET\/CT Physiological Distribution and Pitfalls: Experience in 215 Patients","volume":"41","author":"Calabria","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12149-016-1110-y","article-title":"Carbidopa-assisted 18F-fluorodihydroxyphenylalanine PET\/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors","volume":"30","author":"Helali","year":"2016","journal-title":"Ann. Nucl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00259-018-4245-3","article-title":"Early 18F-FDOPA PET\/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma","volume":"46","author":"Amodru","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00259-014-2943-z","article-title":"18F-FDOPA PET\/CT imaging of insulinoma revisited","volume":"42","author":"Imperiale","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_84","unstructured":"(2020, May 30). Clinical Value of 18F-FDOPA PET\/CT with Contrast Enhancement and without Carbidopa Premedication in Patients with Insulinoma. Available online: http:\/\/ar.iiarjournals.org.ezproxy.unibo.it\/content\/38\/1\/353.long."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3748\/wjg.v19.i6.829","article-title":"Diagnosis and management of insulinoma","volume":"19","author":"Okabayashi","year":"2013","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(13)70049-4","article-title":"Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: A prospective multicentre imaging study","volume":"1","author":"Christ","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.nucmedbio.2019.08.002","article-title":"[68Ga]Ga-NOTA-MAL-Cys39-exendin-4, a potential GLP-1R targeted PET tracer for the detection of insulinoma","volume":"74\u201375","author":"Zhang","year":"2019","journal-title":"Nucl. Med. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7150\/thno.33410","article-title":"PET\/MRI enables simultaneous in vivo quantification of \u03b2-cell mass and function","volume":"10","author":"Michelotti","year":"2020","journal-title":"Theranostics"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1097\/RLU.0000000000002155","article-title":"68Ga DOTA-Exendin PET\/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia","volume":"43","author":"Parihar","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cen.12973","article-title":"Application of Ga(68)-DOTA-exendin-4 PET\/CT to localize an occult insulinoma","volume":"84","author":"Cuthbertson","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1097\/RLU.0000000000003124","article-title":"Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging","volume":"45","author":"Antwi","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ccr3.1448","article-title":"Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET\/CT and 68Ga-DOTATATE PET\/CT","volume":"6","author":"Bongetti","year":"2018","journal-title":"Clin. Case Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2967\/jnumed.110.085142","article-title":"Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas","volume":"52","author":"Wild","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jlcr.3750","article-title":"Exendin--4 analogs in insulinoma theranostics","volume":"62","author":"Jansen","year":"2019","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_95","unstructured":"(2020, September 25). In Vivo Imaging of GLP-1R with a Targeted Bimodal PET\/Fluorescence Imaging Agent|Bioconjugate Chemistry. Available online: https:\/\/pubs.acs.org\/doi\/10.1021\/bc500178d."},{"key":"ref_96","first-page":"109","article-title":"Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4\u2014Impact on the feasibility of insulinoma internal radiotherapy","volume":"5","author":"Velikyan","year":"2015","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.beem.2016.01.003","article-title":"Gastroenteropancreatic neuroendocrine tumours (GEP-NET)\u2014Imaging and staging","volume":"30","author":"Baumann","year":"2016","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","article-title":"Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications","volume":"53","author":"Fani","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.117.199737","article-title":"Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study","volume":"59","author":"Nicolas","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2967\/jnumed.117.199760","article-title":"Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET\/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study","volume":"59","author":"Nicolas","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2967\/jnumed.119.235093","article-title":"Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET\/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study","volume":"61","author":"Zhu","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00259-018-4193-y","article-title":"Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors","volume":"46","author":"Krebs","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2967\/jnumed.111.087999","article-title":"PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: The chelate makes the difference","volume":"52","author":"Fani","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2967\/jnumed.117.205161","article-title":"Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists","volume":"59","author":"Bodei","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1158\/1078-0432.CCR-19-1026","article-title":"Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan","volume":"25","author":"Krebs","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.5760","article-title":"CXCR4 chemokine receptor overview: Biology, pathology and applications in imaging and therapy","volume":"3","author":"Jacobson","year":"2013","journal-title":"Theranostics"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000329873","article-title":"The expression of the hypoxia markers CA9 and CXCR4 is correlated with survival in patients with neuroendocrine tumours of the ileum","volume":"95","author":"Deschamps","year":"2012","journal-title":"Neuroendocrinology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"27566","DOI":"10.18632\/oncotarget.4491","article-title":"Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy","volume":"6","author":"Kaemmerer","year":"2015","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cmdc.201100320","article-title":"PET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand","volume":"6","author":"Demmer","year":"2011","journal-title":"Chemmedchem"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7150\/thno.18754","article-title":"Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors\u2014A Triple Tracer Comparative Approach","volume":"7","author":"Werner","year":"2017","journal-title":"Theranostics"},{"key":"ref_111","first-page":"102","article-title":"Incidental diagnosis of neuroendocrine tumor with 68Ga-PSMA PET\/CT: Report of clinical case","volume":"39","author":"Morales","year":"2020","journal-title":"Rev. Esp. Med. Nucl. E Imagen Mol. Engl. Ed."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/RLU.0000000000002997","article-title":"68Ga-Prostate-Specific Membrane Antigen Uptake in a Pancreatic Neuroendocrine Tumor","volume":"45","author":"Luong","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2019.08.006","article-title":"Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours","volume":"76\u201377","author":"Gaertner","year":"2019","journal-title":"Nucl. Med. Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nucmedbio.2020.07.008","article-title":"Automated production of [18F]SiTATE on a Scintomics GRPTM platform for PET\/CT imaging of neuroendocrine tumors","volume":"88\u201389","author":"Lindner","year":"2020","journal-title":"Nucl. Med. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Pauwels, E., Cleeren, F., Tshibangu, T., Koole, M., Serdons, K., Dekervel, J., Van Cutsem, E., Verslype, C., Van Laere, K., and Bormans, G. (2020). [18F]AlF-NOTA-octreotide PET imaging: Biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur. J. Nucl. Med. Mol. Imaging.","DOI":"10.1007\/s00259-020-04918-4"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/12\/1059\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:41:51Z","timestamp":1760179311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/12\/1059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":115,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["diagnostics10121059"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics10121059","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,7]]}}}